FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200501854> ?p ?o ?g. }

• W4200501854 endingPage "P230" @default.
• W4200501854 startingPage "P230" @default.
• W4200501854 abstract "Abstract BACKGROUND Activating EGFR mutations such as exon 19 deletion (ex19del) and L858R mutations, exon 19 insertions (ex19ins), and point mutations L861Q, G719X, and S768I are oncogenic drivers in lung adenocarcinoma, the most common NSCLC subtype. Although EGFR-targeted therapies, including first-, second-, and third-generation tyrosine kinase inhibitors (TKIs), have improved outcomes in patients (pts) with EGFR-mutant (EGFRm) NSCLC, resistance to these drugs is inevitable. BLU-945 is an investigational fourth-generation EGFR TKI designed to suppress both activating and on-target resistance EGFR mutations, such as C797S and T790M. Preclinical data showed BLU-945 has nanomolar potency against EGFRm/T790M double and EGFRm/T790M/C797S triple mutants with &gt;450-fold selectivity for these mutants over wild-type EGFR in biochemical and cellular assays, and demonstrated robust preclinical antitumor activity, including in intracranial tumors harboring these mutations, providing the therapeutic rationale for BLU-945 clinical development. METHODS BLU-945-1101 (NCT04862780) is an international, open-label, first-in-human, phase 1/2 study designed to evaluate safety, tolerability, and antitumor activity of BLU-945 in pts with EGFRm NSCLC. Key eligibility criteria include adults with pathologically confirmed metastatic NSCLC with an activating EGFR mutation per local assessment (including ex19del or L858R); Eastern Cooperative Oncology Group performance status 0–2; and previous treatment with ≥1 EGFR-targeted TKI. Pts with asymptomatic brain metastases and on stable doses of corticosteroids are eligible. Key exclusion criteria are any additional known primary driver alterations, including but not limited to pathologic aberrations of EGFR exon 20 (insertions), KRAS, BRAF V600E, NTRK1/2/3, HER2, ALK, ROS1, MET, or RET. Phase 1 primary endpoints are maximum tolerated dose, recommended phase 2 dose (RP2D), and safety. The phase 2 primary endpoint is overall response rate (ORR) by RECIST 1.1. Phase 1 secondary endpoints include ORR, duration of response (DOR), pharmacokinetics (PK), and pharmacodynamics (PD); phase 2 secondary endpoints include DOR, disease control rate (DCR), clinical benefit rate (CBR), progression free survival (PFS), overall survival (OS), time to intracranial progression and intracranial response rate, PK, PD, and safety. Phase 1 dose escalation (N≈60) will be conducted using Bayesian optimal interval design. In the phase 2 dose expansion (N≈61), pts will be enrolled into 3 groups based on mutation profile and treated at the RP2D: primary group 1 for pts with EGFR T790M and C797S (n≈37); exploratory group 2 for pts with EGFR T790M but not C797S (n≈12); exploratory group 3 for pts with EGFR C797S but not T790M (n≈12). Group 1 will use Simon’s 2-stage design to test the null hypothesis of ORR ≤20% against a 1-sided alternative of ≥40%. Pts may receive treatment until disease progression or unacceptable toxicity. Recruitment has started and approximately 30 sites will be open for enrollment across North America, Europe, and Asia. Citation Format: David Spigel, Koichi Goto, D. Ross Camidge, Yasir Elamin, Adrianus J. de Langen, Natasha B. Leighl, Anna Minchom, Zofia Piotrowska, David Planchard, Karen Reckamp, Faris Albayya, Jennifer Green, Sean Kim, Melinda Louie-Gao, Renata Sawtell, Alena Zalutskaya, Byoung Chul Co. A phase 1/2 study of BLU-945, a highly potent and selective inhibitor of epidermal growth factor receptor (EGFR) resistance mutations, in patients with EGFR-mutant non-small cell lung cancer (NSCLC) [abstract]. In: Proceedings of the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics; 2021 Oct 7-10. Philadelphia (PA): AACR; Mol Cancer Ther 2021;20(12 Suppl):Abstract nr P230." @default.
• W4200501854 created "2021-12-31" @default.
• W4200501854 creator A5004494246 @default.
• W4200501854 creator A5012748795 @default.
• W4200501854 creator A5014622513 @default.
• W4200501854 creator A5018054038 @default.
• W4200501854 creator A5028596081 @default.
• W4200501854 creator A5037461196 @default.
• W4200501854 creator A5040851961 @default.
• W4200501854 creator A5051283101 @default.
• W4200501854 creator A5055781187 @default.
• W4200501854 creator A5064961562 @default.
• W4200501854 creator A5066714040 @default.
• W4200501854 creator A5069070706 @default.
• W4200501854 creator A5072939839 @default.
• W4200501854 creator A5073435303 @default.
• W4200501854 creator A5073795960 @default.
• W4200501854 creator A5082499548 @default.
• W4200501854 creator A5082517668 @default.
• W4200501854 date "2021-12-01" @default.
• W4200501854 modified "2023-10-16" @default.
• W4200501854 title "Abstract P230: A phase 1/2 study of BLU-945, a highly potent and selective inhibitor of epidermal growth factor receptor (EGFR) resistance mutations, in patients with <i>EGFR</i>-mutant non-small cell lung cancer (NSCLC)" @default.
• W4200501854 doi "https://doi.org/10.1158/1535-7163.targ-21-p230" @default.
• W4200501854 hasPublicationYear "2021" @default.
• W4200501854 type Work @default.
• W4200501854 citedByCount "4" @default.
• W4200501854 countsByYear W42005018542022 @default.
• W4200501854 countsByYear W42005018542023 @default.
• W4200501854 crossrefType "journal-article" @default.
• W4200501854 hasAuthorship W4200501854A5004494246 @default.
• W4200501854 hasAuthorship W4200501854A5012748795 @default.
• W4200501854 hasAuthorship W4200501854A5014622513 @default.
• W4200501854 hasAuthorship W4200501854A5018054038 @default.
• W4200501854 hasAuthorship W4200501854A5028596081 @default.
• W4200501854 hasAuthorship W4200501854A5037461196 @default.
• W4200501854 hasAuthorship W4200501854A5040851961 @default.
• W4200501854 hasAuthorship W4200501854A5051283101 @default.
• W4200501854 hasAuthorship W4200501854A5055781187 @default.
• W4200501854 hasAuthorship W4200501854A5064961562 @default.
• W4200501854 hasAuthorship W4200501854A5066714040 @default.
• W4200501854 hasAuthorship W4200501854A5069070706 @default.
• W4200501854 hasAuthorship W4200501854A5072939839 @default.
• W4200501854 hasAuthorship W4200501854A5073435303 @default.
• W4200501854 hasAuthorship W4200501854A5073795960 @default.
• W4200501854 hasAuthorship W4200501854A5082499548 @default.
• W4200501854 hasAuthorship W4200501854A5082517668 @default.
• W4200501854 hasConcept C104317684 @default.
• W4200501854 hasConcept C121608353 @default.
• W4200501854 hasConcept C126322002 @default.
• W4200501854 hasConcept C143065580 @default.
• W4200501854 hasConcept C143998085 @default.
• W4200501854 hasConcept C2776256026 @default.
• W4200501854 hasConcept C2777506169 @default.
• W4200501854 hasConcept C2777626846 @default.
• W4200501854 hasConcept C2777930144 @default.
• W4200501854 hasConcept C2778087573 @default.
• W4200501854 hasConcept C2779438470 @default.
• W4200501854 hasConcept C2780580887 @default.
• W4200501854 hasConcept C36823959 @default.
• W4200501854 hasConcept C501734568 @default.
• W4200501854 hasConcept C502942594 @default.
• W4200501854 hasConcept C54355233 @default.
• W4200501854 hasConcept C71924100 @default.
• W4200501854 hasConcept C86803240 @default.
• W4200501854 hasConceptScore W4200501854C104317684 @default.
• W4200501854 hasConceptScore W4200501854C121608353 @default.
• W4200501854 hasConceptScore W4200501854C126322002 @default.
• W4200501854 hasConceptScore W4200501854C143065580 @default.
• W4200501854 hasConceptScore W4200501854C143998085 @default.
• W4200501854 hasConceptScore W4200501854C2776256026 @default.
• W4200501854 hasConceptScore W4200501854C2777506169 @default.
• W4200501854 hasConceptScore W4200501854C2777626846 @default.
• W4200501854 hasConceptScore W4200501854C2777930144 @default.
• W4200501854 hasConceptScore W4200501854C2778087573 @default.
• W4200501854 hasConceptScore W4200501854C2779438470 @default.
• W4200501854 hasConceptScore W4200501854C2780580887 @default.
• W4200501854 hasConceptScore W4200501854C36823959 @default.
• W4200501854 hasConceptScore W4200501854C501734568 @default.
• W4200501854 hasConceptScore W4200501854C502942594 @default.
• W4200501854 hasConceptScore W4200501854C54355233 @default.
• W4200501854 hasConceptScore W4200501854C71924100 @default.
• W4200501854 hasConceptScore W4200501854C86803240 @default.
• W4200501854 hasIssue "12_Supplement" @default.
• W4200501854 hasLocation W42005018541 @default.
• W4200501854 hasOpenAccess W4200501854 @default.
• W4200501854 hasPrimaryLocation W42005018541 @default.
• W4200501854 hasRelatedWork W1546552389 @default.
• W4200501854 hasRelatedWork W2143913849 @default.
• W4200501854 hasRelatedWork W2896568882 @default.
• W4200501854 hasRelatedWork W2921871143 @default.
• W4200501854 hasRelatedWork W2954675170 @default.
• W4200501854 hasRelatedWork W2977536616 @default.
• W4200501854 hasRelatedWork W2981539075 @default.
• W4200501854 hasRelatedWork W3000070469 @default.
• W4200501854 hasRelatedWork W3013327955 @default.
• W4200501854 hasRelatedWork W3113842366 @default.
• W4200501854 hasVolume "20" @default.
• W4200501854 isParatext "false" @default.

• next